Showing results (101-110 of 431) with videos related to

Sort By:
Pageof 44
Cancer Science|September 12, 2003
Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivoTsugitaka Natsume, Jun-ichi Watanabe, Yasuhiro Koh, et al.
Japanese Journal of Clinical Oncology|September 23, 2020
Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessmentTomoki Nishida, Yuji Matsumoto, Shinji Sasada, et al.
Asia-Pacific Journal of Clinical Oncology|March 8, 2016
Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patientsYoshinori Makino, Michiko Watanabe, Reiko Ando Makihara, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC)Satoshi Ishikura, Yuichiro Ohe, Keiji Nihei, et al.
The Annals of Thoracic Surgery|November 29, 2021
Salvage Surgery Compared to Surgery After Induction Chemoradiation Therapy for Advanced Lung CancerAki K Kobayashi, Kazuo Nakagawa, Yuko Nakayama, et al.
JTO Clinical and Research Reports|May 2, 2022
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With AlectinibYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.
Japanese Journal of Clinical Oncology|March 24, 2022
The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance studyYuichiro Ohe, Naoya Yamazaki, Nobuyuki Yamamoto, et al.
Clinical Lung Cancer|May 29, 2012
Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancerSeiji Niho, Kaoru Kubota, Keiji Nihei, et al.
Clinical Lung Cancer|November 13, 2020
Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLCYuki Takeyasu, Tatsuya Yoshida, Ryota Shibaki, et al.
Japanese Journal of Clinical Oncology|August 12, 2006
Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patientsYasuhito Fujisaka, Tomohide Tamura, Yuichiro Ohe, et al.
Pageof 44